DelveInsight’s “Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tenosynovial Giant Cell Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Tenosynovial Giant Cell Tumors drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Tenosynovial Giant Cell Tumors treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Tenosynovial Giant Cell Tumors (TSGCTs): An Overview
Tenosynovial giant cell tumors (TSGCTs) are rare, locally aggressive, typically benign neoplasms of joints, bursae, and tendon sheaths. TSGCTs can be roughly divided into localized and diffused types. Giant cell tumor of tendon sheath is the most common form of TSGCT.
They are caused by a translocation of certain parts of chromosomes 1 and 2 causing the cells to overproduce a protein called colony-stimulating factor-1 or CSF-1. There are no environmental, genetic, occupational, lifestyle, demographic, or regional risk factors that have been conclusively shown to be involved with the development of these tumors. TSGCTs have a wide clinical spectrum that affects patients of all ages. The signs and symptoms of TSGCTs can vary depending on the exact location involved and the subtype present.
They are divided into types based on location and how quickly they grow. Localized giant cell tumors grow slowly. They start in smaller joints like the hand and are known as giant cell tumors of the tendon sheath (GCTTS). Diffuse giant cell tumors grow quickly and affect large joints like the knee, hip, ankle, shoulder, or elbow. These tumors are called pigmented villonodular synovitis (PVNS).
The diagnosis of TSGCT is based on a description of the symptoms and physical examinations. In addition, magnetic resonance imaging (MRI) is usually necessary in order to see the lesions and determine the best surgical intervention. Other tests that may help with the diagnosis include X-rays, synovial fluid samples from around the joints, and a biopsy of tissues from the joint.
Surgical resection continues to be the mainstay of treatment for patients with localized and diffused TSGCT. The significant rates of recurrence and risks associated with surgery point to the need for novel systemic treatments for patients with symptomatic advanced TSGCT. The recent approval of systemic therapy for selected adults with symptomatic TSGCT underscores the need for improved and more coordinated multidisciplinary care.
Tenosynovial Giant Cell Tumors (TSGCTs) Market Key Facts
In 2022, the Tenosynovial Giant Cell Tumors Market size was the highest in the US among the 7MM, accounting for approximately USD 150 million, which is further expected to increase by 2032.
Among EU4 countries, Germany accounts for the maximum market size in 2022, while Spain occupies the bottom of the ladder in 2022.
The total incident population of TSGCTs in the 7MM was estimated to be 33,500+ cases in 2021, which is anticipated to increase in the forecasted period.
In Japan, the Incident Cases of Tenosynovial Giant Cell Tumor (TSGCTs) were found to be 4,800+ cases of (TSGCTs) in 2021, this accounts for 14% of the total incident cases of TSGCTs in the 7MM.
As per our analysis, for growth pattern-specific incidence of TSGCTs total incident population of localized TSGCTs in the United States was 12,800+, and that of diffuse TSGCTs was 1,400+ in 2021.
The incident cases of TSGCTs in EU4 and the UK were 14,400+ in 2021, these cases will increase by 2032. Among the European countries, Germany has the highest incident population with 3,700+ cases followed by France and the UK with 2,900+ cases. The lowest incident cases were observed in Spain with 2,100+ cases in 2021.
The total incident population of TSGCTs in EU4 and the UK was 43% of the total incident population among the 7MM in 2021.
Daiichi Sankyo’s TURALIO is the only FDA-approved Tenosynovial Giant Cell Tumors therapy. However, a significant number of patients still use an off-label treatment like imatinib due to TURALIO’s problematic safety and tolerability profile.
The expected launch of vimseltinib (Deciphera Pharmaceuticals) and emactuzumab (SynOx Therapeutics, a subsidiary of Celleron Therapeutics) in 2025 is set to bring major changes in the treatment landscape of Tenosynovial Giant Cell Tumor, bringing in safer and more effective treatment options for Tenosynovial Giant Cell Tumor patients.
Other emerging therapies include AmMax Bio’s AMB-05X, Novartis Pharmaceuticals’ lacnotuzumab, and Abbisko Therapeutics’ pimicotinib, which are in the early developmental stage.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Tenosynovial Giant Cell Tumors pipeline therapies. It also thoroughly assesses the Tenosynovial Giant Cell Tumors market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Tenosynovial Giant Cell Tumors drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Tenosynovial Giant Cell Tumors epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Tenosynovial Giant Cell Tumors epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Tenosynovial Giant Cell Tumors Epidemiology, Segmented as –
Incident cases of Tenosynovial Giant Cell Tumor
Growth-pattern-specific incident cases of Tenosynovial Giant Cell Tumor
Gender-specific incident cases of localized Tenosynovial Giant Cell Tumor
Gender-specific incident cases of diffuse Tenosynovial Giant Cell Tumor
Tumor localization of localized Tenosynovial Giant Cell Tumor
Tumor localization of diffuse Tenosynovial Giant Cell Tumor
Total treated cases of Tenosynovial Giant Cell Tumor
Tenosynovial Giant Cell Tumors (TSGCTs) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to be launched during the study period. The analysis covers the Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Tenosynovial Giant Cell Tumors drugs based on their sale and market share.
The report also covers the Tenosynovial Giant Cell Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Tenosynovial Giant Cell Tumors companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Tenosynovial Giant Cell Tumors Market Will Evolve and Grow by 2032 @
Tenosynovial Giant Cell Tumors Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Tenosynovial Giant Cell Tumors. Currently, Deciphera Pharmaceuticals is leading the therapeutics market with its Tenosynovial Giant Cell Tumors drug candidates in the most advanced stage of clinical development.
In June 2020, the European approval of TURALIO was rejected due to its potentially life-threatening hepatotoxic effects, leading to an unfavorable risk–benefit ratio in the treatment of the non-fatal condition of Tenosnovial Giant Cell Tumor.
Tenosynovial Giant Cell Tumors Companies Actively Working in the Therapeutics Market Include
AmMax Bio, Inc.
Abbisko Therapeutics Co, Ltd.
Hutchison Medipharma Limited
And Many Others
Emerging and Marketed Tenosynovial Giant Cell Tumors Therapies Covered in the Report Include:
Vimseltinib: Deciphera Pharmaceuticals
EI-1071: Elixiron Immunotherapeutics
TURALIO (pexidartinib): Daiichi Sankyo
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tenosynovial Giant Cell Tumors Competitive Intelligence Analysis
4. Tenosynovial Giant Cell Tumors Market Overview at a Glance
5. Tenosynovial Giant Cell Tumors Disease Background and Overview
6. Tenosynovial Giant Cell Tumors Patient Journey
7. Tenosynovial Giant Cell Tumors Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Tenosynovial Giant Cell Tumors Treatment Algorithm, Current Treatment, and Medical Practices
9. Tenosynovial Giant Cell Tumors Unmet Needs
10. Key Endpoints of Tenosynovial Giant Cell Tumors Treatment
11. Tenosynovial Giant Cell Tumors Marketed Therapies
12. Tenosynovial Giant Cell Tumors Emerging Drugs and Latest Therapeutic Advances
13. Tenosynovial Giant Cell Tumors Seven Major Market Analysis
14. Attribute Analysis
15. Tenosynovial Giant Cell Tumors Market Outlook (In US, EU5, and Japan)
16. Tenosynovial Giant Cell Tumors Companies Active in the Market
17. Tenosynovial Giant Cell Tumors Access and Reimbursement Overview
18. KOL Views on the Tenosynovial Giant Cell Tumors Market
19. Tenosynovial Giant Cell Tumors Market Drivers
20. Tenosynovial Giant Cell Tumors Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Encephalomyelitis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Encephalomyelitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Encephalomyelitis market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States